Impact of a restrictive antibiotic policy on the acquisition of extended-spectrum beta-lactamase-producing Enterobacteriaceae in an endemic region: a before-and-after, propensity-matched cohort study in a Caribbean intensive care unit.
Adult
Aged
Anti-Bacterial Agents
/ administration & dosage
Antimicrobial Stewardship
/ methods
Cohort Studies
Endemic Diseases
Enterobacter
/ metabolism
Enterobacteriaceae Infections
/ drug therapy
Female
Health Policy
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Propensity Score
Retrospective Studies
Statistics, Nonparametric
beta-Lactamases
/ metabolism
Antibiotic stewardship
Antimicrobial resistance
Caribbean
ESBL-E colonization
Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae
Intensive care unit
Intestinal microbiota
Journal
Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902
Informations de publication
Date de publication:
26 07 2021
26 07 2021
Historique:
received:
30
04
2021
accepted:
27
06
2021
entrez:
27
7
2021
pubmed:
28
7
2021
medline:
21
10
2021
Statut:
epublish
Résumé
High-level antibiotic consumption plays a critical role in the selection and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) in the ICU. Implementation of a stewardship program including a restrictive antibiotic policy was evaluated with respect to ESBL-E acquisition (carriage and infection). We implemented a 2-year, before-and-after intervention study including all consecutive adult patients admitted for > 48 h in the medical-surgical 26-bed ICU of Guadeloupe University Hospital (French West Indies). A conventional strategy period (CSP) including a broad-spectrum antibiotic as initial empirical treatment, followed by de-escalation (period before), was compared to a restrictive strategy period (RSP) limiting broad-spectrum antibiotics and shortening their duration. Antibiotic therapy was delayed and initiated only after microbiological identification, except for septic shock, severe acute respiratory distress syndrome and meningitis (period after). A multivariate Cox proportional hazard regression model adjusted on propensity score values was performed. The main outcome was the median time of being ESBL-E-free in the ICU. Secondary outcome included all-cause ICU mortality. The study included 1541 patients: 738 in the CSP and 803 in the RSP. During the RSP, less patients were treated with antibiotics (46.8% vs. 57.9%; p < 0.01), treatment duration was shorter (5 vs. 6 days; p < 0.01), and administration of antibiotics targeting anaerobic pathogens significantly decreased (65.3% vs. 33.5%; p < 0.01) compared to the CSP. The incidence of ICU-acquired ESBL-E was lower (12.1% vs. 19%; p < 0.01) during the RSP. The median time of being ESBL-E-free was 22 days (95% CI 16-NA) in the RSP and 18 days (95% CI 16-21) in the CSP. After propensity score weighting and adjusted analysis, the median time of being ESBL-E-free was independently associated with the RSP (hazard ratio, 0.746 [95% CI 0.575-0.968]; p = 0.02, and hazard ratio 0.751 [95% CI 0.578-0.977]; p = 0.03, respectively). All-cause ICU mortality was lower in the RSP than in the CSP (22.5% vs. 28.6%; p < 0.01). Implementation of a program including a restrictive antibiotic strategy is feasible and is associated with less ESBL-E acquisition in the ICU without any worsening of patient outcome.
Sections du résumé
BACKGROUND
High-level antibiotic consumption plays a critical role in the selection and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) in the ICU. Implementation of a stewardship program including a restrictive antibiotic policy was evaluated with respect to ESBL-E acquisition (carriage and infection).
METHODS
We implemented a 2-year, before-and-after intervention study including all consecutive adult patients admitted for > 48 h in the medical-surgical 26-bed ICU of Guadeloupe University Hospital (French West Indies). A conventional strategy period (CSP) including a broad-spectrum antibiotic as initial empirical treatment, followed by de-escalation (period before), was compared to a restrictive strategy period (RSP) limiting broad-spectrum antibiotics and shortening their duration. Antibiotic therapy was delayed and initiated only after microbiological identification, except for septic shock, severe acute respiratory distress syndrome and meningitis (period after). A multivariate Cox proportional hazard regression model adjusted on propensity score values was performed. The main outcome was the median time of being ESBL-E-free in the ICU. Secondary outcome included all-cause ICU mortality.
RESULTS
The study included 1541 patients: 738 in the CSP and 803 in the RSP. During the RSP, less patients were treated with antibiotics (46.8% vs. 57.9%; p < 0.01), treatment duration was shorter (5 vs. 6 days; p < 0.01), and administration of antibiotics targeting anaerobic pathogens significantly decreased (65.3% vs. 33.5%; p < 0.01) compared to the CSP. The incidence of ICU-acquired ESBL-E was lower (12.1% vs. 19%; p < 0.01) during the RSP. The median time of being ESBL-E-free was 22 days (95% CI 16-NA) in the RSP and 18 days (95% CI 16-21) in the CSP. After propensity score weighting and adjusted analysis, the median time of being ESBL-E-free was independently associated with the RSP (hazard ratio, 0.746 [95% CI 0.575-0.968]; p = 0.02, and hazard ratio 0.751 [95% CI 0.578-0.977]; p = 0.03, respectively). All-cause ICU mortality was lower in the RSP than in the CSP (22.5% vs. 28.6%; p < 0.01).
CONCLUSIONS
Implementation of a program including a restrictive antibiotic strategy is feasible and is associated with less ESBL-E acquisition in the ICU without any worsening of patient outcome.
Identifiants
pubmed: 34311760
doi: 10.1186/s13054-021-03660-z
pii: 10.1186/s13054-021-03660-z
pmc: PMC8311634
doi:
Substances chimiques
Anti-Bacterial Agents
0
beta-Lactamases
EC 3.5.2.6
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
261Informations de copyright
© 2021. The Author(s).
Références
Crit Care Med. 2016 Feb;44(2):256-64
pubmed: 26496448
Lancet Infect Dis. 2017 Sep;17(9):990-1001
pubmed: 28629876
Crit Care. 2014 Nov 30;18(6):671
pubmed: 25672873
Crit Care Res Pract. 2014;2014:480463
pubmed: 25525515
Intensive Care Med. 2020 Feb;46(2):236-244
pubmed: 32025778
Intensive Care Med. 2018 Feb;44(2):189-196
pubmed: 29288367
Crit Care. 2011;15(6):R267
pubmed: 22085732
Intensive Care Med. 2018 Mar;44(3):300-310
pubmed: 29484469
Microb Genom. 2019 May;5(5):
pubmed: 31038449
Infect Control Hosp Epidemiol. 2014 Mar;35(3):278-84
pubmed: 24521594
Intensive Care Med. 2016 Dec;42(12):2063-2065
pubmed: 26289014
Intensive Care Med. 2019 Feb;45(2):172-189
pubmed: 30659311
Intensive Care Med. 2012 Nov;38(11):1769-78
pubmed: 22893223
Emerg Infect Dis. 2007 Aug;13(8):1144-9
pubmed: 17953083
Clin Infect Dis. 2019 May 30;68(12):2125-2130
pubmed: 30312366
Crit Care Med. 2013 Jul;41(7):1656-63
pubmed: 23528805
N Engl J Med. 2015 May 21;372(21):1996-2005
pubmed: 25992746
Infect Dis (Lond). 2015;47(11):789-95
pubmed: 26136072
Ann Fr Anesth Reanim. 2009 Oct;28(10):912-20
pubmed: 19880271
Infect Control Hosp Epidemiol. 2018 Nov;39(11):1381-1383
pubmed: 30157988
Intensive Care Med. 2017 Oct;43(10):1464-1475
pubmed: 28733718
Clin Infect Dis. 2017 Apr 1;64(7):870-876
pubmed: 28034888
J Hosp Med. 2012 Nov-Dec;7(9):672-8
pubmed: 22865497
Intensive Care Med. 2020 Apr;46(4):783-786
pubmed: 31776593
Chest. 2005 Dec;128(6):3854-62
pubmed: 16354854
Crit Care Med. 2015 Sep;43(9):1907-15
pubmed: 26121073
Clin Infect Dis. 2017 May 15;64(suppl_2):S51-S60
pubmed: 28475791
Microb Drug Resist. 2014 Feb;20(1):45-51
pubmed: 23692050
Clin Microbiol Infect. 2018 Jan;24(1):3-5
pubmed: 28970162
Intensive Care Med. 2016 Jul;42(7):1159-63
pubmed: 26846513
Intensive Care Med. 2017 Mar;43(3):304-377
pubmed: 28101605
Clin Microbiol Infect. 2015 Jul;21(7):649.e1-10
pubmed: 25882363
Clin Infect Dis. 2018 May 2;66(10):1631-1635
pubmed: 29182749
Lancet Glob Health. 2018 Jun;6(6):e619-e629
pubmed: 29681513
Lancet Infect Dis. 2012 Oct;12(10):774-80
pubmed: 22951600